Q-omics provides the consensus-scored PNPLA2 profile across patient tissues and cancer cell-line models. PNPLA2 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, PNPLA2 is differentially expressed in 13, with the highest sampling consensus in BRCA. Additionally, PNPLA2 RNA expression shows 19,279 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight BRCA, and ACC as cancer lineages where PNPLA2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PNPLA2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PNPLA2 survival associations across molecular data types. PNPLA2 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PNPLA2 RNA expression–survival associations across cancer types. High PNPLA2 expression shows unfavorable associations in LGG, ACC and LUSC, but favorable associations in BRCA, SCLC and HNSC. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for PNPLA2 RNA expression.
This table summarizes PNPLA2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in BRCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PNPLA2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PNPLA2 shows lower tumor expression in BRCA, LUAD, LUSC and KICH and higher tumor expression in LIHC and STAD. The BRCA box plot shows higher PNPLA2 RNA expression in normal versus tumor tissue (log2 FC = −1.689, t-test p < 0.001).
This table shows molecular features associated with PNPLA2 in patient tissues and cancer cell lines. In patient samples, PNPLA2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, PNPLA2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and UPPER_AERODIGESTIVE_TRACT.
